跨性别男性雄激素治疗对卵巢、乳腺及代谢的影响
本文综述了跨性别男性接受性别肯定激素治疗(GAHT)后卵巢、乳腺及代谢(体成分、胰岛素抵抗、骨密度、心血管风险因素等)的变化。长期雄激素治疗对乳腺呈萎缩效应,无乳腺癌风险增加证据;卵巢在治疗6个月后出现类似多囊卵巢综合征的形态学改变但不影响窦卵泡计数;代谢指标与顺性别男性相当,骨密度无不利影响,心血管风险数据总体令人放心但部分研究结论矛盾。
要点
- 长期雄激素治疗使乳腺萎缩,目前无乳腺癌风险增加证据。
- 治疗6个月后卵巢出现类似多囊卵巢综合征的形态学改变,窦卵泡计数不受影响。
- 代谢指标与顺性别男性相当,骨密度无不利影响,血压升高和HDL-C降低是报告的风险因素。
核心结论
- 长期雄激素治疗对跨性别男性乳腺呈萎缩效应,无乳腺癌风险增加证据。
- 卵巢在治疗6个月后出现类似多囊卵巢综合征的形态学改变,但不影响窦卵泡计数。
- 代谢指标与顺性别男性相当,骨密度无不利影响,心血管风险数据总体令人放心但部分研究结论矛盾。
研究设计与样本
- 本文为文献综述,讨论成年跨性别男性接受性别肯定激素治疗后卵巢、乳腺及代谢变化的现有知识。
主要发现
- 长期雄激素治疗对乳腺呈萎缩效应,目前无乳腺癌风险增加证据。
- 长期睾酮治疗6个月后卵巢出现宏观和微观形态学改变,类似多囊卵巢综合征但无窦卵泡计数影响。
- 代谢方面血脂谱、胰岛素抵抗和总体死亡率与顺性别男性相当,多数跨性别男性体成分按期望改变,胰岛素抵抗随男性化降低。
- 骨密度无不利影响;血压升高和高密度脂蛋白胆固醇降低被报告为风险因素,红细胞增多症罕见且可治疗。
临床怎么用
- 临床应关注雄激素治疗后的血压升高和高密度脂蛋白胆固醇降低等心血管风险因素。
- 红细胞增多症罕见且可治疗,需监测但不必过度担忧。
- 心理压力和生活方式因素在综合管理中常被忽视,应纳入整体评估。
局限性
- 大多数现有数据为观察性研究,基于生化标志物而非直接测量心血管损伤。
- 对观察到的变化缺乏解释,部分研究结论矛盾。
- 心理压力和生活方式因素在综合方法中常被遗忘。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Gender-affirming hormone therapy (GAHT) is often provided to transgender people. In this review of the literature, the current knowledge of ovarian, breast, and metabolic changes (body composition, insulin resistance, bone density, cardiovascular risk factors such as lipids, blood pressure, and hematocrit) observed following GAHT in adult transgender men is discussed. A body of literature concurs to describe that long-term androgen therapy in transgender men exerts atrophic effects on the breast. There is currently no evidence of an increased risk of breast cancer. Long-term testosterone treatment induces ovarian effects that become visible after 6 months of therapy. These changes consist of both macroscopic and microscopic alterations of ovarian morphology that mimic the typical ovarian aspect encountered in women with polycystic ovary syndrome but without an effect on antral follicle count. Metabolic effects of long-term androgen treatment in transgender men put them at par with cisgender men in terms of lipid profile, insulin resistance, and overall mortality. Body composition changes as desired after testosterone administration in most transgender men, and insulin resistance decreases with virilization. There are no detrimental effects on bone mineral density. Cardiometabolic risk and morbidity data are currently reassuring, even if certain studies show conflicting results. An increase in blood pressure and a decrease in high-density lipoprotein cholesterol have been reported as risk factors, whereas polycythemia is rare and treatable. Most available data are observational and based on biochemical markers instead of the more direct measures of cardiovascular damage. An explanation for these observed changes is mostly lacking. Psychological stress and lifestyle factors are often forgotten in a much needed integrated approach.
引用
- Pirtea P, Ayoubi JM, Desmedt S, et al. Ovarian, breast, and metabolic changes induced by androgen treatment in transgender men. Fertil Steril. 2021. PMID: 34481638. doi:10.1016/j.fertnstert.2021.07.1206
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。